If you have been reading about certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
The French pressure cell press, or French press, is an apparatus used in biological experimentation to disrupt the plasma membrane of cells by passing them through a narrow valve under high pressure. The French press can also be used for disintegration of chloroplasts, homogenates of animal tissue, and other biological particles. It is capable of disrupting cell walls while leaving the cell nucleus undisturbed. The French press was invented by Charles Stacy French of the Carnegie Institution of Washington. The press uses an external hydraulic pump to drive a piston within a larger cylinder that contains the liquid sample. The highly pressurized sample is then squeezed past a needle valve. As the sample passes through the valve, the fluid experiences shear stress and decompression, causing cellular disruption. The major components of a French press are made of stainless steel to prevent sample contamination. A French press is commonly used to break the resilient plasma membrane and cell walls of bacteria and other microorganisms for isolation of proteins and other cellular components. The disruption of cells in a French press generates 'inside-out' membrane vesicles which are required for many in vitro biochemical assays. The cell is typically chilled overnight before use to preserve enzymatic activities. Disadvantages of the press include that it is not well suited for processing large sample volumes, and is somewhat difficult to operate as a result of the large weight of the assembly (about 14 kg).
=== Brust-Schiffrin method === This method was discovered by Brust and Schiffrin in the early 1990s, and can be used to produce gold nanoparticles in organic liquids that are normally not miscible with water (like toluene). It involves the reaction of a chlorauric acid solution with tetraoctylammonium bromide (TOAB) solution in toluene and sodium borohydride as an anti-coagulant and a reducing agent, respectively. Here, the gold nanoparticles will be around 5–6 nm. NaBH4 is the reducing agent, and TOAB is both the phase transfer catalyst and the stabilizing agent. TOAB does not bind to the gold nanoparticles particularly strongly, so the solution will aggregate gradually over the course of approximately two weeks. To prevent this, one can add a stronger binding agent, like a thiol (in particular, alkanethiols), which will bind to gold, producing a near-permanent solution. Alkanethiol protected gold nanoparticles can be precipitated and then redissolved. Thiols are better binding agents because there is a strong affinity for the gold-sulfur bonds that form when the two substances react with each other. Tetra-dodecanthiol is a commonly used strong binding agent to synthesize smaller particles. Some of the phase transfer agent may remain bound to the purified nanoparticles, this may affect physical properties such as solubility. In order to remove as much of this agent as possible, the nanoparticles must be further purified by soxhlet extraction.
=== EC 1.2.3 With oxygen as acceptor === EC 1.2.3.1: aldehyde oxidase EC 1.2.3.2: Now EC 1.17.3.2, xanthine oxidase EC 1.2.3.3: pyruvate oxidase EC 1.2.3.4: oxalate oxidase EC 1.2.3.5: glyoxylate oxidase EC 1.2.3.6: pyruvate oxidase (CoA-acetylating) EC 1.2.3.7: indole-3-acetaldehyde oxidase EC 1.2.3.8: pyridoxal oxidase EC 1.2.3.9: aryl-aldehyde oxidase EC 1.2.3.10: deleted, activity due to EC 1.2.2.4 carbon-monoxide dehydrogenase (cytochrome b-561) EC 1.2.3.11: Now included with EC 1.2.3.1, aldehyde oxidase EC 1.2.3.12: Now included with EC 1.2.3.1, aldehyde oxidase EC 1.2.3.13: Now EC 1.14.13.82, vanillate monooxygenase EC 1.2.3.14: Abscisic-aldehyde oxidase EC 1.2.3.15: (methyl)glyoxal oxidase
Sources: en.wikipedia.org
All heavier elements (including those necessary for rocky planets like the Earth, and for carbon-based or other life) have thus been created since the Big Bang in stars which were hot enough to fuse helium itself. All elements other than hydrogen and helium today account for only 2% of the mass of atomic matter in the universe. Helium-4, by contrast, comprises about 24% of the mass of the universe's ordinary matter—nearly all the ordinary matter that is not hydrogen.
However, in polluted urban areas, lichen bodies often die before reaching these later developmental stages. Morphological effects of pollution include smaller thalli, fewer and smaller apothecia, and weaker substrate attachment at later developmental stages. Rather than accelerating development under stress, as some plant species do, X. parietina exhibits retarded development of pregenerative individuals and elimination of less tolerant generative individuals. Its pollution tolerance also varies with light availability; optimal conditions appear to be in areas with low pollution and good illumination, where young generative individuals dominate and reproductive capacity is highest. The species also demonstrates high metal tolerance. A key mechanism is the immobilization of toxic metals in the apoplast (the extracellular space between the cell wall and plasma membrane), preventing them from entering living cells. Additionally, it produces protective thiol peptides, increases antioxidant production, and maintains membrane integrity under metal stress. Laboratory studies indicate differential sensitivity to various metals, with its tolerance being higher for cadmium and nickel but lower for copper and mercury. It also shows resilience to pesticide exposure, persisting in untreated gardens but declining in semi-intensive orchards and disappearing in intensively sprayed orchards. These physiological responses to various pollutants make this species valuable for environmental monitoring applications.
== Academic career == Over the course of his academic career at Harvard University and the Harvard Medical School, Verdine has elucidated the molecular mechanism of epigenetic DNA methylation and pathways by which certain genotoxic forms of DNA damage are surveilled in and eradicated from the genome. As a professor, Verdine introduced biological principles into organic chemistry courses and helped found two fields of science that meld basic research and new medicines discovery: chemical biology, which enlists chemistry to answer biological questions; and new modalities, which works to discover and develop novel structural classes of therapeutics. He has served as the Erving Professor of Chemistry in the Departments of Stem Cell and Regenerative Biology and Chemistry and Chemical Biology at Harvard University since 1988. In 2013, he stepped down from his tenured professorship at Harvard, taking a leave of absence in order to focus full-time on steering Warp Drive Bio as CEO while continuing to run his eponymous Verdine Laboratory at the Harvard University Department of Stem Cell & Regenerative Biology. The laboratory focused on research based in chemical biology, including synthetic biologics and genomic research,. He has since transitioned to a 'professor of the practice' position at Harvard.
Art museums include the Sabauda Gallery, the Museo Civico d'Arte Antica, Pinacoteca Giovanni e Marella Agnelli, the Accademia Albertina, the Gallery of Modern and Contemporary Art, and the Diocesan Museum of Turin. After it had been little more than a town for a long time, in 1559 the Duke Emmanuel Philibert of Savoy made Turin the capital of his domains. The Duke had the ambition to transform the city into a major artistic and cultural capital, and in the following centuries numerous artists were to work at the Savoy court, especially architects and planners such as Carlo di Castellamonte and his son Amedeo, Guarino Guarini and, in the 18th century, Filippo Juvarra and Benedetto Alfieri. As for the painting and the visual arts, Turin became a point of reference, especially in the 20th century. In the 1920s, the painter Felice Casorati inspired a number of students called The group of six of Turin and these included Carlo Levi, Henry Paolucci, Gigi Chessa, Francesco Menzio, Nicola Galante and Jessie Boswell. Artists born in Turin include the sculptor Umberto Mastroianni and the architect Carlo Mollino. Between the 1960s and the 1970s, the international centre of Turin (Arte Povera), the presence in the city of artists such as Alighiero Boetti, Mario Merz, Giuseppe Penone, Piero Gilardi and Michelangelo Pistoletto. In those years there was a strong artistic influence of designer Armando Testa. Artists currently operating in the city include Ugo Nespolo and Carol Rama.
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.